EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

DIO Corporation (039840) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of DIO Corporation KRW 10,782, price KRW 9,430, upside +14.3%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · KR · ISIN KR7039840004

DC Some data Sep 24, 2026

DIO Corporation

039840 · KQ

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value 10,782 KRW · Undervalued (+14%)
✓Quality 68/100
!Mixed Growth (revenue 5y +6.4 %/yr)
!Thin margins · 4.8% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (4/10)
!Narrow moat 36/100
!Evidence only medium, so the estimate is less certain
!Weak on past: 17 out of 100
!Weak on dividend: 21 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

53,700 KRW 9,430 KRW Fair Value 10,782 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 9,430 KRW – 53,700 KRW · fair‑value band 7,446 KRW – 14,119 KRW · the 9,430 KRW price screens below the 10,782 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow DIO in your weekly email

Every Wednesday you see whether DIO is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DIO Corporation manufactures and sells dental implants in South Korea and internationally. The company offers UFII implant internal submerged and no-submerged systems, FTN implant external systems, protem implants, and UV active implant systems. It also provides digital dental implant solutions; and dental products and cardiovascular medical devices.

Show more

DIO Corporation manufactures and sells dental implants in South Korea and internationally. The company offers UFII implant internal submerged and no-submerged systems, FTN implant external systems, protem implants, and UV active implant systems. It also provides digital dental implant solutions; and dental products and cardiovascular medical devices. The company was formerly known as DSI Co., Ltd and changed its name to DIO Corporation in August 2008. DIO Corporation was founded in 1988 and is headquartered in Busan, South Korea.

Stock analysis

DIO Corporation (039840) currently trades at 9,430 KRW, while our model-based Fair Value estimate is 10,782 KRW, implying the stock looks roughly 12.5% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 15,680 KRW per share, and 11 of the 14 models we run sit above the 9,430 KRW price.

Bear case: the Earnings-Based group reads lowest at 7,002 KRW, and 3 of the 14 models stay below the price. Evidence for this calculation is medium.

Scenario range: 7,446 KRW (bear) to 14,119 KRW (bull), the price of 9,430 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

DIO Corporation reported revenue of 164B KRW in FY2025 versus 150B KRW in FY2021, a compound +2.3%/yr. Reported net income was −1.4B KRW in FY2025.

Key figures

Market cap 156B KRW (≈ $115M) · P/S ratio 0.92 · Dividend yield 1.1% · Net margin −0.8% · Return on equity 4.2% · Return on assets (EBIT) 0.1% · Operating margin 5.2% · Revenue (TTM) 170B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades about 51% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at 14%, 039840 screens cheaper than that median.

Fair Value models

Bear 7,446 KRW Fair Value 10,782 KRW Bull 14,119 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 12,593 KRW 19,441 KRW 29,386 KRW 80
Growth DCF 12,361 KRW 18,219 KRW 26,093 KRW 78
Owner Earnings 6,334 KRW 9,369 KRW 13,777 KRW 76
All 14 models by family
DCF Models
FCF DCF 12,593 KRW 19,441 KRW 29,386 KRW 80
Owner Earnings 6,334 KRW 9,369 KRW 13,777 KRW 76
5Y Revenue Exit 10,022 KRW 15,301 KRW 22,277 KRW 72
5Y EBITDA Exit 14,467 KRW 24,516 KRW 37,122 KRW 74
10Y Revenue Exit 10,751 KRW 15,680 KRW 22,909 KRW 66
10Y EBITDA Exit 13,462 KRW 21,470 KRW 33,583 KRW 67
Earnings-Based
EPV 6,397 KRW 7,002 KRW 7,494 KRW 74
Multiples
EV/EBIT 11,359 KRW 14,695 KRW 18,031 KRW 66
EV/EBITDA 17,241 KRW 22,539 KRW 27,836 KRW 67
EV/Revenue 8,494 KRW 11,555 KRW 14,617 KRW 54
Asset-Based
NCAV (Graham) 7,446 KRW 9,977 KRW 14,891 KRW 54
Growth DCF
Growth DCF 12,361 KRW 18,219 KRW 26,093 KRW 78
Rev-Margin DCF 10,022 KRW 15,282 KRW 22,140 KRW 72
Economic Profit
ROIC Compounder 6,397 KRW 7,002 KRW 7,494 KRW 72

Open the full fair value analysis →

Notify me when 039840 reaches fair value

Put 039840 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 68/100

Of which business quality 63 · Market factors (momentum, volatility) 26

Profitability 26
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 47
Earnings quality: real cash, not paper profit
Fin. Strength 51
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 5
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+37.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Start year 2020 (pandemic). Over 10 years: +8.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
24.3% (2020) → 6.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+19.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +3.3% a year for the price and +16.8% for the forecasts.
Forecast 2026 (sales)+19.7%
Forecast 2027 (sales)+23.1%
Projected 2028 (sales)+20.5%
Projected 2029 (sales)+17.9%
Projected 2030 (sales)+15.2%

Watch 039840, get fair value alerts →

Compare DIO Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 204 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside +14% · Above median
Profitability
Return on equity (TTM) 4% · Below median
Return on assets 2% · Below median
Net margin (TTM) 5% · Below median
Operating margin (TTM) 5% · Below median
Growth and dividend
Revenue growth 15% · Above median
Dividend yield (TTM) 1.1% · Below median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/FCF 0.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)52 · sector 14
FUTURE (revenue growth)77 · sector 31
PAST (return on equity)17 · sector 25
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)21 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $399.52 $348.72 −13%
EssilorLuxottica Société anonyme EL €144.70 €159.17 +10%
Medline Inc MDLN $34.30 $30.15 −12%
Becton, Dickinson and Company BDX $182.52 $103.53 −43%
Alcon Inc ALC $65.39 $39.78 −39%
ResMed Inc RMD A$31.70 A$34.87 +10%
West Pharmaceutical Services, Inc WST $375.87 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €215.80 €54.82 −75%
Straumann Holding STMN CHF 96.38 CHF 45.50 −53%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "DIO Corporation Fair Value". https://www.fairvalue-calculator.com/stock/039840

Frequently asked questions

Is DIO Corporation (039840) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10,782 KRW versus a price of 9,430 KRW, about +14% upside (undervalued).
What is the fair value of 039840?
Our model-based fair value for DIO Corporation is 10,782 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 9,430 KRW.
What is the quality score of 039840?
DIO Corporation has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DIO Corporation (039840)?
Our model-based price target is the fair value of 10,782 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 7,446 KRW, optimistic scenario 14,119 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DIO Corporation stock forecast for 2026?
Our models put fair value at 10,782 KRW, about +14% upside versus a price of 9,430 KRW (undervalued). Cautious scenario 7,446 KRW, optimistic scenario 14,119 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DIO Corporation (039840)?
DIO Corporation reported trailing-twelve-month revenue of about 170B KRW (latest available figure, as of Sep 24, 2026).
Does DIO Corporation pay a dividend?
DIO Corporation currently shows a dividend yield of about 1.05% relative to its recent price (as of Sep 24, 2026).
What growth is priced into DIO Corporation (039840)?
For today's price to be fair in a discounted-cash-flow model, DIO Corporation would have to grow free cash flow by +5.5 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 039840 use?
Our models discount DIO Corporation at 11.6 %: a base by market capitalisation (micro), damped by beta 0.51, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DIO Corporation that is +5.5 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has DIO Corporation (039840) delivered so far?
Over the past 5 years revenue at DIO Corporation grew +6.5 % a year. The price currently implies +5.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DIO Corporation (039840) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into DIO Corporation (+5.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DIO Corporation (039840)?
The free-cash-flow yield on the price is 9.18 %: that much free cash flow DIO Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DIO Corporation (039840)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DIO Corporation it is 10,782 KRW per share (as of Sep 24, 2026), against a price of 9,430 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is DIO Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 039840 trades below its calculated fair value: price 9,430 KRW, fair value 10,782 KRW, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 039840?
No. The price is what the market pays today (9,430 KRW); the fair value is what the company's own numbers justify (10,782 KRW). For DIO Corporation the two are 1,352 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DIO Corporation worth?
The market values DIO Corporation at about 156B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 9,430 KRW; our models calculate a fair value of 10,782 KRW per share.
What do the bullish and bearish scenarios say about 039840?
Our models span a range for DIO Corporation: cautious scenario 7,446 KRW, base 10,782 KRW, optimistic 14,119 KRW per share (as of Sep 24, 2026, price 9,430 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DIO Corporation (039840)?
Balance-sheet figures for DIO Corporation (as of Sep 24, 2026): return on equity 4.2%, debt of 0.13 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 039840 from its 52-week high?
DIO Corporation trades at 9,430 KRW, about 51% below its 52-week high of 19,300 KRW and at the low of 9,430 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 10,782 KRW is for.
Which stocks are comparable to DIO Corporation?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DIO Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 9,430 KRW, calculated fair value 10,782 KRW (+14%), Quality Score 68/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 039840 calculated?
We run DIO Corporation through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10,782 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. DIO Corporation currently trades 14 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DIO Corporation (039840)?
The closing price on Sep 23, 2026 was 9,430 KRW. Our model-based fair value is 10,782 KRW, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DIO Corporation right now?
A fairly wide model range (7,446 KRW to 14,119 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of DIO Corporation

How large is the market capitalisation of DIO Corporation (039840)?
The market capitalisation of DIO Corporation is 156B KRW (≈ $115M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DIO Corporation (039840)?
The price-to-sales ratio of DIO Corporation is 0.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of DIO Corporation (039840)?
The dividend yield of DIO Corporation is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DIO Corporation (039840)?
The net margin of DIO Corporation is −0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DIO Corporation (039840)?
The return on equity (ROE) of DIO Corporation is 4.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DIO Corporation (039840)?
On an EBIT basis the return on assets of DIO Corporation is 0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DIO Corporation (039840)?
The operating margin of DIO Corporation is 5.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DIO Corporation (039840)?
Revenue at DIO Corporation is growing +15.4% versus a year earlier (3y avg +7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DIO Corporation (039840)?
Earnings per share at DIO Corporation are growing +74.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DIO Corporation (039840) carry?
The net debt of DIO Corporation is 33.0B KRW (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch DIO Corporation in the live analysis

One click puts DIO Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.